In support of this claim, a recent study showed that activation of Janus kinase 2 (JAK2) signaling associated with myeloproliferative neoplasms (MPNs) resulted in reduced expression of proteostasis component AIRAPL (arsenite-inducible RNA-associated protein-like) and led to increased insulin/insulin-like growth factor 1 (IGF1R) stability and disrupted hematopoietic differentiation [62]. The gene discussed is IGF1R; the disease is myeloproliferative disorder.